

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>New hypoglycemic agents and the kidney: what do the... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1844/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1844" />
    
            <meta name="description" content="Read the original article in full on F1000Research: New hypoglycemic agents and the kidney: what do the major trials tell us?" />
    
            <meta name="og:title" content="F1000Research Article: New hypoglycemic agents and the kidney: what do the major trials tell us?.">
            <meta name="og:description" content="Read the latest article version by Brendan Smyth, Vlado Perkovic, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="17620">
            <meta name="article-id" content="16135">
            <meta name="dc.title" content="New hypoglycemic agents and the kidney: what do the major trials tell us?">
            <meta name="dc.description" content="As the burden of diabetic kidney disease continues to expand, new therapies to preserve renal function or prevent diabetic nephropathy are urgently needed. In the past decade, a number of new hypoglycemic classes have emerged, each with a unique profile of action and benefits. Here we review the impact of glycemic control on renal outcomes and the results of the major clinical trials of&amp;nbsp;glucagon-like peptide 1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium&ndash;glucose co-transporter 2 (SGLT2) inhibitors. Both GLP-1 agonists and SGLT2 inhibitors consistently demonstrate renal benefits.&amp;nbsp;Further studies of these new agents in different patient groups and in comparison to (or in combination with) other treatments are required to better define their role in combating the burden of diabetic kidney disease.">
            <meta name="dc.subject" content="Chronic Kidney Disease, Diabetic nephropathy, macroalbuminuria, empagliflozin, canagliflozin, SGLT2, GLP-1, liraglutide, semaglutide, saxagliptin, alogliptin, DPP-4">
            <meta name="dc.creator" content="Smyth, Brendan">
            <meta name="dc.creator" content="Perkovic, Vlado">
            <meta name="dc.date" content="2018/11/23">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.16135.1">
            <meta name="dc.source" content="F1000Research 2018 7:1844">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Chronic Kidney Disease">
            <meta name="prism.keyword" content="Diabetic nephropathy">
            <meta name="prism.keyword" content="macroalbuminuria">
            <meta name="prism.keyword" content="empagliflozin">
            <meta name="prism.keyword" content="canagliflozin">
            <meta name="prism.keyword" content="SGLT2">
            <meta name="prism.keyword" content="GLP-1">
            <meta name="prism.keyword" content="liraglutide">
            <meta name="prism.keyword" content="semaglutide">
            <meta name="prism.keyword" content="saxagliptin">
            <meta name="prism.keyword" content="alogliptin">
            <meta name="prism.keyword" content="DPP-4">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/11/23">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1844">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.16135.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1844">
            <meta name="citation_title" content="New hypoglycemic agents and the kidney: what do the major trials tell us?">
            <meta name="citation_abstract" content="As the burden of diabetic kidney disease continues to expand, new therapies to preserve renal function or prevent diabetic nephropathy are urgently needed. In the past decade, a number of new hypoglycemic classes have emerged, each with a unique profile of action and benefits. Here we review the impact of glycemic control on renal outcomes and the results of the major clinical trials of&amp;nbsp;glucagon-like peptide 1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium&ndash;glucose co-transporter 2 (SGLT2) inhibitors. Both GLP-1 agonists and SGLT2 inhibitors consistently demonstrate renal benefits.&amp;nbsp;Further studies of these new agents in different patient groups and in comparison to (or in combination with) other treatments are required to better define their role in combating the burden of diabetic kidney disease.">
            <meta name="citation_description" content="As the burden of diabetic kidney disease continues to expand, new therapies to preserve renal function or prevent diabetic nephropathy are urgently needed. In the past decade, a number of new hypoglycemic classes have emerged, each with a unique profile of action and benefits. Here we review the impact of glycemic control on renal outcomes and the results of the major clinical trials of&amp;nbsp;glucagon-like peptide 1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium&ndash;glucose co-transporter 2 (SGLT2) inhibitors. Both GLP-1 agonists and SGLT2 inhibitors consistently demonstrate renal benefits.&amp;nbsp;Further studies of these new agents in different patient groups and in comparison to (or in combination with) other treatments are required to better define their role in combating the burden of diabetic kidney disease.">
            <meta name="citation_keywords" content="Chronic Kidney Disease, Diabetic nephropathy, macroalbuminuria, empagliflozin, canagliflozin, SGLT2, GLP-1, liraglutide, semaglutide, saxagliptin, alogliptin, DPP-4">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Brendan Smyth">
            <meta name="citation_author_institution" content="The George Institute for Global Health, UNSW, Sydney, Australia">
            <meta name="citation_author" content="Vlado Perkovic">
            <meta name="citation_author_institution" content="The George Institute for Global Health, UNSW, Sydney, Australia">
            <meta name="citation_publication_date" content="2018/11/23">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1844">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.16135.1">
            <meta name="citation_firstpage" content="1844">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1844/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1844.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=17620 /> <input type=hidden id=articleId name=articleId value=16135 /> <input type=hidden id=xmlUrl value="/articles/7-1844/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1844-v1.xml"> <input type=hidden id=article_uuid value=2ddda9f0-ba04-4af3-bfa7-5a847c59fc96 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="New hypoglycemic agents and the kidney: what do the major trials tell us?"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.16135.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.16135.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1844"
  },
  "headline": "New hypoglycemic agents and the kidney: what do the major trials tell us?",
  "datePublished": "2018-11-23T11:58:50",
  "dateModified": "2018-11-23T11:58:50",
  "author": [
    {
      "@type": "Person",
      "name": "Brendan Smyth"
    },    {
      "@type": "Person",
      "name": "Vlado Perkovic"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "As the burden of diabetic kidney disease continues to expand, new therapies to preserve renal function or prevent diabetic nephropathy are urgently needed. In the past decade, a number of new hypoglycemic classes have emerged, each with a unique profile of action and benefits. Here we review the impact of glycemic control on renal outcomes and the results of the major clinical trials of glucagon-like peptide 1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium&ndash;glucose co-transporter 2 (SGLT2) inhibitors. Both GLP-1 agonists and SGLT2 inhibitors consistently demonstrate renal benefits. Further studies of these new agents in different patient groups and in comparison to (or in combination with) other treatments are required to better define their role in combating the burden of diabetic kidney disease."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1844/v1",
            "name": "New hypoglycemic agents and the kidney: what do the major trials tell..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> New hypoglycemic agents and the kidney: what do the major trials tell... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=17620 data-id=16135 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16135.1" data-recommended="" data-doi="10.12688/f1000research.16135.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1844/v1/pdf?article_uuid=2ddda9f0-ba04-4af3-bfa7-5a847c59fc96" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-16135-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-16135-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-16135-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Smyth B and Perkovic V. New hypoglycemic agents and the kidney: what do the major trials tell us? [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1844 (<a class=new-orange href="https://doi.org/10.12688/f1000research.16135.1" target=_blank>https://doi.org/10.12688/f1000research.16135.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-16135-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=16135 id=track-article-signin-16135 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16135?target=/articles/7-1844/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=17620 /> <input name=articleId type=hidden value=16135 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>New hypoglycemic agents and the kidney: what do the major trials tell us?</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Brendan Smyth<a href="https://orcid.org/0000-0003-1838-3348" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1838-3348</div>,&nbsp;</span><span class=""><a href="mailto:VPerkovic@georgeinstitute.org.au" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Vlado Perkovic</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Brendan Smyth<a href="http://orcid.org/0000-0003-1838-3348" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1838-3348</div>,&nbsp;</span><span class=""><a href="mailto:VPerkovic@georgeinstitute.org.au" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Vlado Perkovic</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 23 Nov 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.16135.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> The George Institute for Global Health, UNSW, Sydney, Australia<br/> <p> <div class=margin-bottom> Brendan Smyth <br/> <span>Roles: </span> Investigation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Vlado Perkovic <br/> <span>Roles: </span> Conceptualization, Investigation, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=42019-40886></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=25143-40883></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> As the burden of diabetic kidney disease continues to expand, new therapies to preserve renal function or prevent diabetic nephropathy are urgently needed. In the past decade, a number of new hypoglycemic classes have emerged, each with a unique profile of action and benefits. Here we review the impact of glycemic control on renal outcomes and the results of the major clinical trials of&nbsp;glucagon-like peptide 1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium–glucose co-transporter 2 (SGLT2) inhibitors. Both GLP-1 agonists and SGLT2 inhibitors consistently demonstrate renal benefits.&nbsp;Further studies of these new agents in different patient groups and in comparison to (or in combination with) other treatments are required to better define their role in combating the burden of diabetic kidney disease. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Chronic Kidney Disease, Diabetic nephropathy, macroalbuminuria, empagliflozin, canagliflozin, SGLT2, GLP-1, liraglutide, semaglutide, saxagliptin, alogliptin, DPP-4 </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Vlado Perkovic (<a href="mailto:VPerkovic@georgeinstitute.org.au">VPerkovic@georgeinstitute.org.au</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Vlado Perkovic </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Dr Perkovic is a member of Steering Committees for CREDENCE (Chair, funded by Janssen), CARMELINA (co-chair, Boehringer-Ingelheim and Eli Lilly), MARLINA (BI/Lilly), SONAR (Abbvie), TESTING (NHMRC/Pfizer), RESOLVE (NHMRC), ASCEND (GSK) and has received Honoraria/advisory boards from Abbvie, Astellas, Astra Zeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk and Servier </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Smyth B and Perkovic V. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Smyth B and Perkovic V. New hypoglycemic agents and the kidney: what do the major trials tell us? [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1844 (<a href="https://doi.org/10.12688/f1000research.16135.1" target=_blank>https://doi.org/10.12688/f1000research.16135.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 23 Nov 2018, <b>7</b>(F1000 Faculty Rev):1844 (<a href="https://doi.org/10.12688/f1000research.16135.1" target=_blank>https://doi.org/10.12688/f1000research.16135.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 23 Nov 2018, <b>7</b>(F1000 Faculty Rev):1844 (<a href="https://doi.org/10.12688/f1000research.16135.1" target=_blank>https://doi.org/10.12688/f1000research.16135.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d50940e134>Introduction</h2><p class="" id=d50940e137>In 2016, chronic kidney disease (CKD) due to diabetes mellitus (DM) was responsible for the loss of almost 15 million disability-adjusted life years worldwide, an increase of 25% over the preceding 10 years<sup><a href="#ref-1">1</a></sup>. Despite important advances in therapy, it still constitutes a major challenge to patients, clinicians, and healthcare services and results in dramatically shortened lifespan, lower quality of life, and increased healthcare costs<sup><a href="#ref-2">2</a></sup>. Prevention of advanced diabetic nephropathy by either preventing disease onset or slowing the decline of established CKD is a critical goal of therapy. Angiotensin system blockade is well established as an effective treatment for albuminuria in diabetic nephropathy and is known to slow disease progression<sup><a href="#ref-3">3</a></sup>. Multiple novel agents have been investigated to date but have frequently proven less effective or less well tolerated than current therapies<sup><a href="#ref-4">4</a></sup>. As such, glucose control remains the primary therapy in patients with diabetes. The effect of specific classes of hypoglycemic agents on renal outcomes is therefore a critical consideration in the management of diabetes and diabetic nephropathy. In the past decade, three new classes of hypoglycemic agent have entered the market: glucagon-like peptide 1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium–glucose co-transporter 2 (SGLT2) inhibitors. After reviewing the impact of tight glycemic control on renal disease, this review will focus on the renal outcomes in major trials of these new agents in patients with type 2 DM (T2DM).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d50940e159>Glycemic control and diabetic nephropathy</h2><p class="" id=d50940e162>Our understanding of the impact of glycemic control on diabetic microvascular outcomes in T2DM is derived primarily from a series of large randomized controlled trials (RCTs) of varying glycemic targets. The United Kingdom Prospective Diabetes Study (UKPDS), a watershed in the management of T2DM, demonstrated a reduction in microvascular outcomes (primarily due to a lower rate of retinopathy) with a target fasting glucose of &lt;6 mmol/L versus the conventional target of &lt;15 mmol/L (resulting in a mean HbA1c of 7.0% versus 7.9%, respectively)<sup><a href="#ref-5">5</a></sup>. This was followed a decade later by a cluster of trials––ADVANCE<sup><a href="#ref-6">6</a></sup>, ACCORD<sup><a href="#ref-7">7</a></sup>, and VADT<sup><a href="#ref-8">8</a></sup>––aiming to determine the optimal HbA1c target and enrolling a cohort of generally older participants with a median time since diagnosis of diabetes of 7–10 years, many of whom had established microvascular and/or macrovascular disease. Collectively, these four trials enrolled 27,049 participants with a median follow up of 5.0 years. A recent meta-analysis using individual patient data provides the highest quality evidence for the impact of tighter glycemic control on renal outcomes<sup><a href="#ref-9">9</a></sup>. The mean difference in HbA1c in the more-intensive versus less-intensive arms was approximately 1% (HbA1c 6.80% [95% confidence interval (CI) 6.65, 6.95] versus 7.74% [95% CI 7.34, 8.14], respectively). This was associated with a 20% reduction (hazard ratio [HR] 0.80 [95% CI 0.72, 0.88]) in the composite of end-stage kidney disease (ESKD), renal death, estimated glomerular filtration rate (eGFR) of &lt;30 mL/minute/1.73 m<sup>2</sup>, and new macroalbuminuria<sup><a href="#ref-9">9</a></sup>. This outcome occurred in 1.2% of the more-intensive arm and 1.6% of the less-intensive arm and was primarily driven by a reduction in the rate of transformation from normoalbuminuria (&lt;30 mg/g or &lt;3 mg/mmol) or microalbuminuria (30–300 mg/g or 3–30 mg/mmol) to overt diabetic nephropathy with macroalbuminuria (&gt;300 mg/g or &gt;30 mg/mmol). Interestingly, the risk of decline in eGFR to &lt;30 mL/minute/1.73 m<sup>2</sup> was not affected by tighter glycemic control (HR 1.16 [95% CI 0.93, 1.44]), and, while the ADVANCE trial found a reduced risk of ESKD in participants randomized to tight control<sup><a href="#ref-10">10</a></sup>, this was not seen across the other trials<sup><a href="#ref-9">9</a></sup>. The meta-analysis identified an increased risk of severe hypoglycemia (HR 2.48 [95% CI 1.91, 3.21]) in those treated with intensive glucose lowering and, despite a reduction in major cardiovascular events (HR 0.91 [95% CI 0.84, 0.99]), there was no reduction in all-cause mortality (HR 1.04 [95% CI 0.90, 1.20])<sup><a href="#ref-11">11</a></sup>. Indeed, in the ACCORD study, intensive glucose lowering (achieved median HbA1c of 6.4%) was associated with an increase in mortality (HR 1.22 [95% CI 1.01, 1.46]; <i>p</i>=0.04)<sup><a href="#ref-7">7</a></sup>. While these trials and their subsequent analysis confirm that further modest reductions in renal events are achievable with more-intensive glycemic control, they also highlight the increasing risks and diminishing returns of this approach. These findings suggest the need for further therapies capable of preventing the loss of kidney function independently of reductions in glycemia.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d50940e219>Incretin mimetics and enhancers</h2><p class="" id=d50940e222>Two of the three new classes of hypoglycemic agents, GLP-1 receptor agonists and DPP-4 inhibitors, act by augmenting incretins, a family of gut-derived hormones that potentiate the secretion of insulin while also exerting a variety of potentially beneficial metabolic effects independent of insulin activity, including enhanced satiety, reduced gastric emptying, and intestinal motility, which may lead to reductions in body weight and waist circumference<sup><a href="#ref-12">12</a></sup>. GLP-1 is the most important of the incretin hormones from a therapeutic perspective, as its action can now be modulated either by direct agonism or by inhibition of the enzyme primarily responsible for its breakdown (DPP-4)<sup><a href="#ref-12">12</a></sup>.</p><div class=section><a name=d50940e233 class=n-a></a><h3 class=section-title>Glucagon-like peptide 1 receptor agonists</h3><p class="" id=d50940e238>GLP-1 receptor agonists are peptides administered subcutaneously with substantial homology with endogenous GLP-1 but which are resistant to metabolism by DPP-4. Owing to partial renal clearance, GLP-1 receptor agonists were initially restricted to patients with an eGFR of &gt;30 mL/minute/1.73 m<sup>2</sup><sup><a href="#ref-12">12</a></sup>; however, following further regulatory review, they are now approved for CKD stage 4 in some regions.</p><p class="" id=d50940e247>Four major RCTs have examined the cardiovascular effects of GLP-1 receptor agonists in participants with T2DM and a history or risk of cardiovascular disease: ELIXA (lixisenatide, n=6,068)<sup><a href="#ref-13">13</a></sup>, LEADER (liraglutide, n=9,340)<sup><a href="#ref-14">14</a></sup>, SUSTAIN-6 (semaglutide, n=3,297)<sup><a href="#ref-15">15</a></sup>, and EXSCEL (extended-release exenatide, n=14,752)<sup><a href="#ref-16">16</a></sup>. Meta-analysis of these studies has demonstrated a reduction in risk of all-cause mortality (HR 0.88 [95% CI 0.81, 0.95]), cardiovascular mortality (HR 0.87 [95% CI 0.79, 0.96]), and major adverse cardiovascular events (HR 0.90 [95% CI 0.82, 0.99])<sup><a href="#ref-17">17</a></sup>. Favorable reductions in HbA1c (–0.57% [95% CI –0.74, –0.40]), body weight (–2.25 kg [95% CI –3.09, –1.41]), and systolic blood pressure (–1.33 mmHg [95% CI –1.80, –0.86]) were also reported in a separate meta-analysis<sup><a href="#ref-18">18</a></sup>. In addition to these metabolic benefits, previous studies suggest that GLP-1 receptor agonists have complex intra-renal effects, including natriuresis and afferent arteriolar vasodilation<sup><a href="#ref-12">12</a></sup>. The extent to which the renal hemodynamic effects of GLP-1 receptor agonists affect renal outcomes is not clear. These renal actions of GLP-1 appear complex, with renal afferent arteriolar vasodilation and glomerular hyperfiltration demonstrated in healthy individuals but not in those with T2DM, in whom a reduction in glomerular hyperfiltration or no change has been reported. Subsequent trials have generally not shown acute changes in eGFR when commencing GLP-1 receptor agonists.</p><p class="" id=d50940e279>Three of the four large GLP-1 agonist RCTs have reported renal outcomes. In the LEADER trial, with a reduction in HbA1c of approximately 1.0% in the first 12 months (decreasing to 0.4% at 36 months) and of 2.5 kg in bodyweight, the composite renal outcome (new macroalbuminuria, doubling of creatinine, eGFR of ≤45 mL/minute/1.73 m<sup>2</sup>, and renal replacement therapy [RRT] or renal death) was reduced significantly in the liraglutide arm (HR 0.78 [95% CI 0.67, 0.92]) driven by a reduction in macroalbuminuria (9.0% versus 12.1%)<sup><a href="#ref-14">14</a></sup>. A reduction in the rate of decline in renal function was also noted in post-hoc analyses<sup><a href="#ref-19">19</a></sup>. Overall, the rate of decline was 2% lower in the liraglutide group (a difference of doubtful clinical importance); however, in those with impaired renal function at baseline (eGFR 30–59 mL/minute/1.73 m<sup>2</sup>), the rate of decline was 2 mL/minute/1.73 m<sup>2</sup> per year in the liraglutide group as compared to 4 mL/minute/1.73 m<sup>2</sup> per year in the placebo group (<i>p</i>&lt;0.001). No effect was observed on the risk of ESKD (HR 0.87 [95% CI 0.61, 1.24]). The results of SUSTAIN-6 were similar, with a similar renal composite endpoint (not including renal death) being less frequent in the treatment group (HR 0.64 [95% CI 0.46, 0.88])<sup><a href="#ref-15">15</a></sup>, although it is not known if rate of decline in eGFR was affected by semaglutide, as this analysis has not been published to date. The ELIXA trial demonstrated that lixisenatide was associated with a lower risk of new-onset macroalbuminuria (HR 0.81 [95% CI 0.66, 0.99]), but there was no difference in decline in eGFR or doubling of serum creatinine (although the number of events was small)<sup><a href="#ref-20">20</a></sup>. Finally, a recent randomized study in 577 participants with stage 3–4 CKD and T2DM showed that glycemic control and safety of dulaglutide were similar to insulin glargine. Patients treated with dulaglutide sustained approximately 2 kg of weight loss and had lower rates of hypoglycemia. There was a significant difference between decline in cystatin C-eGFR in the dulaglutide arm and the insulin arm over 12 months (–0.7 mL/minute/1.73 m<sup>2</sup> versus –3.3 mL/minute/1.73 m<sup>2</sup>; <i>p</i>&lt;0.05), but this did not reach significance when measured by creatinine-eGFR<sup><a href="#ref-21">21</a></sup>. It remains unclear whether dulaglutide affects the underlying rate of decline in eGFR or the development of ESKD.</p></div><div class=section><a name=d50940e329 class=n-a></a><h3 class=section-title>Dipeptidyl peptidase 4 (DPP-4) inhibitors</h3><p class="" id=d50940e334>Our understanding of the renal effects of DPP-4 inhibitors is derived from four large placebo-controlled RCTs<sup><a href="#ref-12">12</a></sup>. These trials have shown these agents to be safe in patients with CKD, but the benefits appear to be limited to modest improvements in albuminuria. Moreover, no reductions in major cardiovascular events were demonstrated<sup><a href="#ref-22">22</a>–<a href="#ref-25">25</a></sup>. In the 16,492 participants in the SAVOR-TIMI 53 trial of saxagliptin versus placebo<sup><a href="#ref-25">25</a></sup>, there was a significant difference in the number with stable or improved albuminuria category in favor of the saxagliptin arm (after a median follow up of 2.1 years). At the 2-year follow up point, mean albumin creatinine ratio was lower by 34.3 mg/g (3.88 mg/mmol) (<i>p</i>&lt;0.004). The reduction in albuminuria was most marked in participants with an eGFR of &lt;30 mL/minute/1.73 m<sup>2</sup>, although this did not reach significance: 245.2 mg/g (27.7 mg/mmol) (<i>p</i>=0.086). No differences in change in eGFR, doubling of serum creatinine, or ESKD were identified<sup><a href="#ref-26">26</a></sup>. Albuminuria was not studied in the EXAMINE trial of alogliptin after acute coronary syndrome (n=5,380), but, as with saxagliptin, no significant changes in eGFR or ESKD were identified<sup><a href="#ref-24">24</a></sup>. The TECOS trial of sitagliptin versus placebo (n=14,671) also did not demonstrate a difference in rate of decline of renal function, irrespective of eGFR at baseline<sup><a href="#ref-27">27</a></sup>. A trivial difference in urine albumin creatinine ratio was identified (–0.18 mg/g [95% CI –0.35, –0.02]), but there was no difference in incident microalbuminuria or ESKD, even in those with baseline CKD<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. The most recent of these studies, the CARMELINA trial (n=6,979)<sup><a href="#ref-25">25</a></sup>, which enrolled participants with both high cardiovascular risk (a history of vascular disease) and renal risk (reduced eGFR and microalbuminuria or macroalbuminuria), found no difference in rates of the composite renal outcome of ≥40% reduction in eGFR, ESKD, or death from renal failure (HR 1.04 [95% CI 0.89, 1.22]). This was despite a significant reduction in progression of albuminuria (HR 0.86 [95% CI 0.78, 0.95]). Overall, it appears that the impact of DPP-4 inhibitors on renal outcomes is modest at best, a finding supported by a meta-analysis of 36 DPP-4 inhibitor RCTs (excluding CARMELINA) which concluded that there was no impact on the risk of renal failure (RR 1.06 [95% CI 0.88, 1.27])<sup><a href="#ref-29">29</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d50940e394>Sodium–glucose co-transporter 2 inhibitors</h2><p class="" id=d50940e397>SGLT2 inhibitors, a relatively new class of hypoglycemic agent, have demonstrated both cardiovascular and renal benefits<sup><a href="#ref-30">30</a></sup>. Inhibition of SGLT2 results in lowered serum glucose levels via an increase in urinary glucose excretion. This novel mechanism of action also results in an increase in sodium delivery to the distal tubule, triggering tubuloglomerular feedback (via the macula densa) and a reduction in glomerular pressure. A study in 40 participants with T1DM suggests that this mechanism results in reduced renal blood flow and glomerular filtration, particularly in those with baseline hyperfiltration<sup><a href="#ref-31">31</a></sup>. As with angiotensin blockade, this results in a reduction in proteinuria. The net effect of this is a 3–5 mL/minute/1.73 m<sup>2</sup> reduction in eGFR and a reduction in albuminuria, independent of lowering of HbA1c. In addition, the diuretic effect of increased glucose delivery to the distal tubule lowers blood volume and blood pressure and the loss of glucose represents a net loss of calories, contributing to weight loss.</p><p class="" id=d50940e411>Two major clinical trials of SGLT2 inhibitors have been published, with several more in progress<sup><a href="#ref-32">32</a></sup>. The EMPA-REG OUTCOME study of empagliflozin enrolled 7,020 participants with established cardiovascular disease, T2DM, and an eGFR of &gt;30 mL/minute/1.73 m<sup>2</sup> who were followed for a median of 3.1 years<sup><a href="#ref-33">33</a></sup>. The primary outcome of cardiovascular death, myocardial infarction, and stroke was reduced by 14% (HR 0.86 [95% CI 0.74, 0.99]), and there was a 35% reduction in hospitalization for heart failure (HR 0.65 [95% CI 0.50, 0.85]). The composite renal outcome of incident macroalbuminuria, doubling of serum creatinine, eGFR of &lt;45 mL/minute/1.73 m<sup>2</sup>, and RRT or death from renal disease occurred in 12.7% of those assigned to empagliflozin and 18.8% of those in the placebo arm (HR 0.61 [95% CI 0.53, 0.70])<sup><a href="#ref-34">34</a></sup>. This benefit was consistent among subgroups and dose of empagliflozin. Although largely driven by a reduction in progression to macroalbuminuria (11.2% versus 16.2%), the other components of the composite outcome were also significantly reduced by similar relative magnitudes: doubling of serum creatinine (1.5% versus 2.6%) and need for RRT (0.3% versus 0.6%). Empagliflozin also resulted in a significantly lower rate of decline in eGFR: 0.19±0.11 mL/minute/1.73 m<sup>2</sup> per year versus 1.67±0.13 mL/minute/1.73 m<sup>2</sup> per year (after adjusting for the 4–5 mL/minute/1.73 m<sup>2</sup> initial decline in eGFR seen in the initial month of treatment, which was reversible upon trial completion)<sup><a href="#ref-34">34</a></sup>.</p><p class="" id=d50940e446>The CANVAS Program comprised two RCTs comparing canagliflozin to placebo in 10,142 participants with T2DM at high cardiovascular risk (i.e. previous symptomatic coronary artery disease or age over 50 with two risk factors). Participants were followed for a mean of 3.6 years. Like EMPA-REG OUTCOME, the CANVAS trial saw a decrease in major cardiovascular events, heart failure, and composite renal endpoint of sustained doubling of serum creatinine, ESKD, or death from renal causes, which occurred at a rate of 1.5 versus 2.8 per 1,000 patient-years (HR 0.53 [95% CI 0.33, 0.84])<sup><a href="#ref-35">35</a></sup>. There was a 42% reduction in incident macroalbuminuria (HR 0.58 [95% CI 0.50, 0.68]) and a 50% reduction in doubling of serum creatinine (HR 0.50 [95% CI 0.30, 0.84]). There was no significant reduction in ESKD or renal death; however, only 21 events were recorded overall, and the point estimate of effect was consistent with the broader composite outcome (HR 0.56 [95% CI 0.23, 1.32]). Renal function was also stabilized in those on canagliflozin (once the initial 3.1 mL/minute/1.73 m<sup>2</sup> decrease in eGFR was accounted for), with a mean annual change in eGFR of +0.3 mL/minute/1.73 m<sup>2</sup> versus –0.9 mL/minute/1.73 m<sup>2</sup> in those on placebo. This resulted in a mean difference in annual eGFR decline of 1.2 mL/minute/1.73 m<sup>2</sup> per year (95% CI 1.0, 1.4)<sup><a href="#ref-36">36</a></sup>.</p><p class="" id=d50940e470>The most common side effect of SGLT2 inhibitors is fungal genital infections, which affected approximately 5% of male patients and 10% of female patients in both trials<sup><a href="#ref-33">33</a>,<a href="#ref-35">35</a></sup>. There were no increases in bacterial urinary tract infections, including complicated urinary tract infections, nor in the incidence of acute kidney injury. Based on earlier studies, the U.S. Food and Drug Administration (FDA) inserted a label warning regarding acute kidney injury for SGLT2 inhibitors. While cautious initiation (as with any diuretic) is reasonable, the favorable long-term renal effects in both CANVAS and EMPA-REG OUTCOME suggest that any such acute, volume-related renal injury rarely leads to permanent loss of renal function<sup><a href="#ref-37">37</a></sup>. An unexpected increase in the rate of amputations (predominantly toe or metatarsal) was noted with canagliflozin (6.3 versus 3.4 per 1,000 patient-years; HR 1.97 [95% CI 1.41, 2.75])<sup><a href="#ref-35">35</a></sup>. While this has not been noted in the only other completed trial of SGLT2 inhibitors (EMPA-REG OUTCOME), a numerical excess has been observed in the ertugliflozin development program<sup><a href="#ref-38">38</a></sup>. It is thus unclear whether this is a drug effect, class effect, or chance finding<sup><a href="#ref-30">30</a></sup>. Observational studies of these associations have not been consistent<sup><a href="#ref-30">30</a></sup>. Concern has also been raised regarding the increased risk of fractures seen with canagliflozin, including in the CANVAS trial. A meta-analysis identified a 22% increased risk of fractures with canagliflozin (HR 1.22 [95% CI 1.02, 1.46]), but no significant differences for other agents in the SGLT2 class<sup><a href="#ref-37">37</a></sup>, again raising the possibility that this is a drug effect rather than a property of the class. In addition, post-marketing reports to the FDA have highlighted 12 cases of Fournier’s gangrene (necrotizing fasciitis of the perineum), prompting a specific label warning. Finally, cases of diabetic ketoacidosis (DKA) have been reported with SGLT2 inhibitors, mostly in T1DM patients, and, while these appear to be rare in patients with T2DM, it is important that clinicians are aware that patients may present with only mildly elevated blood glucose levels. Reassuringly, there was no significant increase in DKA seen in either the EMPA-REG OUTCOME or the CANVAS trial<sup><a href="#ref-33">33</a>,<a href="#ref-35">35</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d50940e515>Conclusion</h2><p class="" id=d50940e518>To conclude, the range of options for the treatment of T2DM continues to expand. Of the three new classes of hypoglycemic agents released in the past decade, while DPP-4 inhibitors do not appear to have obvious renal benefits, both GLP-1 receptor agonists and SGLT2 inhibitors are now proven to reduce the risk of progression to macroalbuminuria. More importantly, SGLT2 inhibitors also consistently reduce the incidence of progression of CKD, whether measured by doubling of serum creatinine or rate of decline in eGFR. The physiology of these agents, the results of the trials above, and the adverse event profiles suggest that some drug classes may be better suited to particular patient subpopulations and, as yet, these benefits cannot be extrapolated to patients with an eGFR of &lt;30 mL/minute/1.73m<sup>2</sup>, an important group for whom the risks of progressive loss of renal function are highest. Further studies of these new agents in different patient groups and in comparison to (or in combination with) other treatments are required to better define their role in combating the burden of diabetic kidney disease.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d50940e1 class=n-a></a><h2 class=main-title id=d51063>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d50940e528 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d51186>References</h2><div class="section ref-list"><a name=d50940e528 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d50940e535 class=n-a></a>GBD 2016 DALYs and HALE Collaborators: Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet.</i> 2017; <b>390</b>(10100): 1260–344. <a target=xrefwindow id=d50940e543 href="http://www.ncbi.nlm.nih.gov/pubmed/28919118">PubMed Abstract </a> | <a target=xrefwindow id=d50940e546 href="https://doi.org/10.1016/S0140-6736(17)32130-X">Publisher Full Text </a> | <a target=xrefwindow id=d50940e549 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5605707">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d50940e558 class=n-a></a>Neuen BL, Chadban SJ, Demaio AR, <i> et al.</i>: Chronic kidney disease and the global NCDs agenda. <i>BMJ Glob Health.</i> 2017; <b>2</b>(2): e000380. <a target=xrefwindow id=d50940e569 href="http://www.ncbi.nlm.nih.gov/pubmed/29225940">PubMed Abstract </a> | <a target=xrefwindow id=d50940e572 href="https://doi.org/10.1136/bmjgh-2017-000380">Publisher Full Text </a> | <a target=xrefwindow id=d50940e576 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5717948">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d50940e585 class=n-a></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Working Group: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. <i>Kidney Int Suppl.</i> 2013; <b>3</b>(1): 1–150. <a target=xrefwindow id=d50940e593 href="https://www.guidelinecentral.com/summaries/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease/">Reference Source</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d50940e602 class=n-a></a>Cherney DZI, Bakris GL: Novel therapies for diabetic kidney disease. <i>Kidney Int Suppl (2011).</i> 2018; <b>8</b>(1): 18–25. <a target=xrefwindow id=d50940e610 href="https://doi.org/10.1016/j.kisu.2017.10.005">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d50940e619 class=n-a></a>King P, Peacock I, Donnelly R: The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. <i>Br J Clin Pharmacol.</i> 1999; <b>48</b>(5): 643–8. <a target=xrefwindow id=d50940e627 href="http://www.ncbi.nlm.nih.gov/pubmed/10594464">PubMed Abstract </a> | <a target=xrefwindow id=d50940e630 href="https://doi.org/10.1046/j.1365-2125.1999.00092.x">Publisher Full Text </a> | <a target=xrefwindow id=d50940e633 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2014359">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1116712"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e643 class=n-a></a>ADVANCE Collaborative Group, Patel A, MacMahon S, <i> et al.</i>: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. <i>N Engl J Med.</i> 2008; <b>358</b>(24): 2560–72. <a target=xrefwindow id=d50940e654 href="http://www.ncbi.nlm.nih.gov/pubmed/18539916">PubMed Abstract </a> | <a target=xrefwindow id=d50940e657 href="https://doi.org/10.1056/NEJMoa0802987">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1116712">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d50940e670 class=n-a></a>Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, <i> et al.</i>: Effects of intensive glucose lowering in type 2 diabetes. <i>N Engl J Med.</i> 2008; <b>358</b>(24): 2545–59. <a target=xrefwindow id=d50940e681 href="http://www.ncbi.nlm.nih.gov/pubmed/18539917">PubMed Abstract </a> | <a target=xrefwindow id=d50940e684 href="https://doi.org/10.1056/NEJMoa0802743">Publisher Full Text </a> | <a target=xrefwindow id=d50940e688 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4551392">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1145101"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e697 class=n-a></a>Duckworth W, Abraira C, Moritz T, <i> et al.</i>: Glucose control and vascular complications in veterans with type 2 diabetes. <i>N Engl J Med.</i> 2009; <b>360</b>(2): 129–39. <a target=xrefwindow id=d50940e708 href="http://www.ncbi.nlm.nih.gov/pubmed/19092145">PubMed Abstract </a> | <a target=xrefwindow id=d50940e711 href="https://doi.org/10.1056/NEJMoa0808431">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1145101">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727471925"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e724 class=n-a></a>Zoungas S, Arima H, Gerstein HC, <i> et al.</i>: Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes Endocrinol.</i> 2017; <b>5</b>(6): 431–7. <a target=xrefwindow id=d50940e735 href="http://www.ncbi.nlm.nih.gov/pubmed/28365411">PubMed Abstract </a> | <a target=xrefwindow id=d50940e738 href="https://doi.org/10.1016/S2213-8587(17)30104-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727471925">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d50940e751 class=n-a></a>Wong MG, Perkovic V, Chalmers J, <i> et al.</i>: Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. <i>Diabetes Care.</i> 2016; <b>39</b>(5): 694–700. <a target=xrefwindow id=d50940e762 href="http://www.ncbi.nlm.nih.gov/pubmed/27006512">PubMed Abstract </a> | <a target=xrefwindow id=d50940e765 href="https://doi.org/10.2337/dc15-2322">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718381938"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e774 class=n-a></a>Control Group, Turnbull FM, Abraira C, <i> et al.</i>: Intensive glucose control and macrovascular outcomes in type 2 diabetes. <i>Diabetologia.</i> 2009; <b>52</b>(11): 2288–98. <a target=xrefwindow id=d50940e785 href="http://www.ncbi.nlm.nih.gov/pubmed/19655124">PubMed Abstract </a> | <a target=xrefwindow id=d50940e788 href="https://doi.org/10.1007/s00125-009-1470-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718381938">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730591823"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e802 class=n-a></a>Muskiet MHA, Tonneijck L, Smits MM, <i> et al.</i>: GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. <i>Nat Rev Nephrol.</i> 2017; <b>13</b>(10): 605–28. <a target=xrefwindow id=d50940e813 href="http://www.ncbi.nlm.nih.gov/pubmed/28869249">PubMed Abstract </a> | <a target=xrefwindow id=d50940e816 href="https://doi.org/10.1038/nrneph.2017.123">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730591823">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d50940e829 class=n-a></a>Pfeffer MA, Claggett B, Diaz R, <i> et al.</i>: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>N Engl J Med.</i> 2015; <b>373</b>(23): 2247–57. <a target=xrefwindow id=d50940e840 href="http://www.ncbi.nlm.nih.gov/pubmed/26630143">PubMed Abstract </a> | <a target=xrefwindow id=d50940e843 href="https://doi.org/10.1056/NEJMoa1509225">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726419704"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e852 class=n-a></a>Marso SP, Daniels GH, Brown-Frandsen K, <i> et al.</i>: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2016; <b>375</b>(4): 311–22. <a target=xrefwindow id=d50940e863 href="http://www.ncbi.nlm.nih.gov/pubmed/27295427">PubMed Abstract </a> | <a target=xrefwindow id=d50940e866 href="https://doi.org/10.1056/NEJMoa1603827">Publisher Full Text </a> | <a target=xrefwindow id=d50940e870 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4985288">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726419704">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726744841"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e883 class=n-a></a>Marso SP, Bain SC, Consoli A, <i> et al.</i>: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>N Engl J Med.</i> 2016; <b>375</b>(19): 1834–44. <a target=xrefwindow id=d50940e894 href="http://www.ncbi.nlm.nih.gov/pubmed/27633186">PubMed Abstract </a> | <a target=xrefwindow id=d50940e897 href="https://doi.org/10.1056/NEJMoa1607141">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726744841">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d50940e910 class=n-a></a>Holman RR, Bethel MA, Mentz RJ, <i> et al.</i>: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2017; <b>377</b>(13): 1228–39. <a target=xrefwindow id=d50940e921 href="http://www.ncbi.nlm.nih.gov/pubmed/28910237">PubMed Abstract </a> | <a target=xrefwindow id=d50940e924 href="https://doi.org/10.1056/NEJMoa1612917">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732267672"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e933 class=n-a></a>Bethel MA, Patel RA, Merrill P, <i> et al.</i>: Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes Endocrinol.</i> 2018; <b>6</b>(2): 105–13. <a target=xrefwindow id=d50940e944 href="http://www.ncbi.nlm.nih.gov/pubmed/29221659">PubMed Abstract </a> | <a target=xrefwindow id=d50940e947 href="https://doi.org/10.1016/S2213-8587(17)30412-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732267672">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d50940e961 class=n-a></a>Zhang X, Shao F, Zhu L, <i> et al.</i>: Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis. <i>BMC Pharmacol Toxicol.</i> 2018; <b>19</b>(1): 58. <a target=xrefwindow id=d50940e972 href="http://www.ncbi.nlm.nih.gov/pubmed/30223891">PubMed Abstract </a> | <a target=xrefwindow id=d50940e975 href="https://doi.org/10.1186/s40360-018-0246-x">Publisher Full Text </a> | <a target=xrefwindow id=d50940e979 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6142638">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730126538"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e988 class=n-a></a>Mann JFE, Ørsted DD, Brown-Frandsen K, <i> et al.</i>: Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2017; <b>377</b>(9): 839–48. <a target=xrefwindow id=d50940e999 href="http://www.ncbi.nlm.nih.gov/pubmed/28854085">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1002 href="https://doi.org/10.1056/NEJMoa1616011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730126538">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734171559"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1015 class=n-a></a>Muskiet MHA, Tonneijck L, Huang Y, <i> et al.</i>: Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. <i>Lancet Diabetes Endocrinol.</i> 2018; <b>6</b>(11): 859–69. <a target=xrefwindow id=d50940e1026 href="http://www.ncbi.nlm.nih.gov/pubmed/30292589">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1029 href="https://doi.org/10.1016/S2213-8587(18)30268-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734171559">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733467482"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1042 class=n-a></a>Tuttle KR, Lakshmanan MC, Rayner B, <i> et al.</i>: Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. <i>Lancet Diabetes Endocrinol.</i> 2018; <b>6</b>(8): 605–17. <a target=xrefwindow id=d50940e1053 href="http://www.ncbi.nlm.nih.gov/pubmed/29910024">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1056 href="https://doi.org/10.1016/S2213-8587(18)30104-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733467482">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d50940e1069 class=n-a></a>Green JB, Bethel MA, Armstrong PW, <i> et al.</i>: Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2015; <b>373</b>(3): 232–42. <a target=xrefwindow id=d50940e1080 href="http://www.ncbi.nlm.nih.gov/pubmed/26052984">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1083 href="https://doi.org/10.1056/NEJMoa1501352">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718095661"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1092 class=n-a></a>White WB, Cannon CP, Heller SR, <i> et al.</i>: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>N Engl J Med.</i> 2013; <b>369</b>(14): 1327–35. <a target=xrefwindow id=d50940e1103 href="http://www.ncbi.nlm.nih.gov/pubmed/23992602">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1106 href="https://doi.org/10.1056/NEJMoa1305889">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718095661">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718095662"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1120 class=n-a></a>Scirica BM, Bhatt DL, Braunwald E, <i> et al.</i>: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>N Engl J Med.</i> 2013; <b>369</b>(14): 1317–26. <a target=xrefwindow id=d50940e1131 href="http://www.ncbi.nlm.nih.gov/pubmed/23992601">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1134 href="https://doi.org/10.1056/NEJMoa1307684">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718095662">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d50940e1147 class=n-a></a>Rosenstock J, Perkovic V, Johansen OE, <i> et al.</i>: Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. <i>JAMA.</i> 2018. <a target=xrefwindow id=d50940e1155 href="http://www.ncbi.nlm.nih.gov/pubmed/30418475">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1158 href="https://doi.org/10.1001/jama.2018.18269">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d50940e1167 class=n-a></a>Mosenzon O, Leibowitz G, Bhatt DL, <i> et al.</i>: Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care.</i> 2017; <b>40</b>(1): 69–76. <a target=xrefwindow id=d50940e1178 href="http://www.ncbi.nlm.nih.gov/pubmed/27797925">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1181 href="https://doi.org/10.2337/dc16-0621">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d50940e1190 class=n-a></a>Cornel JH, Bakris GL, Stevens SR, <i> et al.</i>: Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care.</i> 2016; <b>39</b>(12): 2304–10. <a target=xrefwindow id=d50940e1201 href="http://www.ncbi.nlm.nih.gov/pubmed/27742728">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1204 href="https://doi.org/10.2337/dc16-1415">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d50940e1213 class=n-a></a>Engel SS, Suryawanshi S, Stevens SR, <i> et al.</i>: Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. <i>Diabetes Obes Metab.</i> 2017; <b>19</b>(11): 1587–93. <a target=xrefwindow id=d50940e1224 href="http://www.ncbi.nlm.nih.gov/pubmed/28432745">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1227 href="https://doi.org/10.1111/dom.12983">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d50940e1236 class=n-a></a>Rehman MB, Tudrej BV, Soustre J, <i> et al.</i>: Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. <i>Diabetes Metab.</i> 2017; <b>43</b>(1): 48–58. <a target=xrefwindow id=d50940e1247 href="http://www.ncbi.nlm.nih.gov/pubmed/27745828">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1250 href="https://doi.org/10.1016/j.diabet.2016.09.005">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733181594"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1260 class=n-a></a>Heerspink HJL, Kosiborod M, Inzucchi SE, <i> et al.</i>: Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. <i>Kidney Int.</i> 2018; <b>94</b>(1): 26–39. <a target=xrefwindow id=d50940e1271 href="http://www.ncbi.nlm.nih.gov/pubmed/29735306">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1274 href="https://doi.org/10.1016/j.kint.2017.12.027">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733181594">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718206836"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1287 class=n-a></a>Cherney DZ, Perkins BA, Soleymanlou N, <i> et al.</i>: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. <i>Circulation.</i> 2014; <b>129</b>(5): 587–97. <a target=xrefwindow id=d50940e1298 href="http://www.ncbi.nlm.nih.gov/pubmed/24334175">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1301 href="https://doi.org/10.1161/CIRCULATIONAHA.113.005081">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718206836">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733388530"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1314 class=n-a></a>Alicic RZ, Johnson EJ, Tuttle KR: SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. <i>Am J Kidney Dis.</i> 2018; <b>72</b>(2): 267–77. <a target=xrefwindow id=d50940e1322 href="http://www.ncbi.nlm.nih.gov/pubmed/29866460">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1325 href="https://doi.org/10.1053/j.ajkd.2018.03.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733388530">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725794423"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1338 class=n-a></a>Zinman B, Wanner C, Lachin JM, <i> et al.</i>: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>N Engl J Med.</i> 2015; <b>373</b>(22): 2117–28. <a target=xrefwindow id=d50940e1349 href="http://www.ncbi.nlm.nih.gov/pubmed/26378978">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1352 href="https://doi.org/10.1056/NEJMoa1504720">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725794423">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726421733"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1365 class=n-a></a>Wanner C, Inzucchi SE, Lachin JM, <i> et al.</i>: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>N Engl J Med.</i> 2016; <b>375</b>(4): 323–34. <a target=xrefwindow id=d50940e1376 href="http://www.ncbi.nlm.nih.gov/pubmed/27299675">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1379 href="https://doi.org/10.1056/NEJMoa1515920">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726421733">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d50940e1392 class=n-a></a>Neal B, Perkovic V, Mahaffey KW, <i> et al.</i>: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>N Engl J Med.</i> 2017; <b>377</b>(7): 644–657. <a target=xrefwindow id=d50940e1403 href="http://www.ncbi.nlm.nih.gov/pubmed/28605608">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1406 href="https://doi.org/10.1056/NEJMc1712572">Publisher Full Text </a></span><div class=note><a name=d50940e1408 class=n-a></a><p class=first id=d50940e1409><a target=xrefwindow href="10.1056/NEJMoa1611925" id=d50940e1410>F1000 Recommendation</a></p></div></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733506952"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d50940e1420 class=n-a></a>Perkovic V, de Zeeuw D, Mahaffey KW, <i> et al.</i>: Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>Lancet Diabetes Endocrinol.</i> 2018; <b>6</b>(9): 691–704. <a target=xrefwindow id=d50940e1431 href="http://www.ncbi.nlm.nih.gov/pubmed/29937267">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1434 href="https://doi.org/10.1016/S2213-8587(18)30141-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733506952">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d50940e1447 class=n-a></a>Rådholm K, Wu JH, Wong MG, <i> et al.</i>: Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review. <i>Diabetes Res Clin Pract.</i> 2018; <b>140</b>: 118–28. <a target=xrefwindow id=d50940e1458 href="http://www.ncbi.nlm.nih.gov/pubmed/29604389">PubMed Abstract </a> | <a target=xrefwindow id=d50940e1461 href="https://doi.org/10.1016/j.diabres.2018.03.027">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d50940e1470 class=n-a></a><a target=xrefwindow id=d50940e1471><a target=xrefwindow id=d50940e1471 href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000SumR.pdfsimple"> https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000SumR.pdf</a></a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 23 Nov 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1844/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1844/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> The George Institute for Global Health, UNSW, Sydney, Australia<br/> <p> <div class=margin-bottom> Brendan Smyth <br/> <span>Roles: </span> Investigation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Vlado Perkovic <br/> <span>Roles: </span> Conceptualization, Investigation, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1844/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 23 Nov 2018, 7:1844 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.16135.1">https://doi.org/10.12688/f1000research.16135.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Smyth B and Perkovic V. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=17620 data-id=16135 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16135.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1844/v1/pdf?article_uuid=2ddda9f0-ba04-4af3-bfa7-5a847c59fc96" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.16135.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Smyth B and Perkovic V. New hypoglycemic agents and the kidney: what do the major trials tell us? [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1844 (<a href="https://doi.org/10.12688/f1000research.16135.1" target=_blank>https://doi.org/10.12688/f1000research.16135.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=16135 id=mobile-track-article-signin-16135 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16135?target=/articles/7-1844/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=17620 /> <input name=articleId type=hidden value=16135 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Dani&euml;l van Raalte</strong>, Diabetes Center, Department of Internal Medicine, VU University Medical Center, The Netherlands </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Advisory boards/consultancy: Astra Zeneca, BI-Eli Lilly Alliance, Novo Nordisk, Merck, Sanofi Research Grants: Astra Zeneca, BI-Eli Lilly Alliance, Novo Nordisk, Sanofi All honoraria/funding is directly transferred to Daniël van Raalte's employer, VUMC. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Itamar Raz</strong>, The Diabetes Research Unit, Internal Medicine Section, Hadassah Hebrew University Hospital, Israel </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Itamar Raz was co-PI for SAVOR TIMI 53 and DECLARE TIMI 58 trials. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 23 Nov 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1844/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1844/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=42019-40886></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=25143-40883></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1844/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>23 Nov 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Dani&euml;l van Raalte</strong>, Diabetes Center, Department of Internal Medicine, VU University Medical Center, The Netherlands </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Advisory boards/consultancy: Astra Zeneca, BI-Eli Lilly Alliance, Novo Nordisk, Merck, Sanofi Research Grants: Astra Zeneca, BI-Eli Lilly Alliance, Novo Nordisk, Sanofi All honoraria/funding is directly transferred to Daniël van Raalte's employer, VUMC. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Itamar Raz</strong>, The Diabetes Research Unit, Internal Medicine Section, Hadassah Hebrew University Hospital, Israel </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Itamar Raz was co-PI for SAVOR TIMI 53 and DECLARE TIMI 58 trials. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1844/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1844/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "New hypoglycemic agents and the kidney: what...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1844/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1844/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1844/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Smyth B and Perkovic V');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1844/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1844",
            templates : {
                twitter : "New hypoglycemic agents and the kidney: what do the major trials.... Smyth B and Perkovic V, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1844/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: New hypoglycemic agents and the kidney: what do the major trials tell us?", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: New hypoglycemic agents and the kidney: what do the major trials tell us?", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/16135/17620")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "17620");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "40883": 0,
                           "40886": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "bb7f26a8-3966-4a9e-bc42-818738b8c32f";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1844.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1844.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1844.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1844.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1844.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>